LinkedIn Profile

Access Alnylam Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Sector Industry
nasdaq:alny 48171 Sep 22nd, 2021 12:00AM Alnylam Pharmaceuticals 108K 1712 Open Biotechnology Sep 22nd, 2021 08:29AM Sep 22nd, 2021 08:29AM To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer for two years in a row ('19-'20), a Boston Globe Top Place to Work 6x in a row ('15-'20) and one of Fast Company's Best Workplaces for Innovators for 2021. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam), Instagram (@AlnylamPharma) and YouTube. See our community guidelines: https://bit.ly/2FcRhJy Open Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, RNAi Open 675 W Kendall St Cambridge Massachusetts US 02142 Health Care Pharmaceuticals & Biotechnology
nasdaq:alny 48171 Sep 21st, 2021 12:00AM Alnylam Pharmaceuticals 108K 1711 Open Biotechnology Sep 21st, 2021 09:10AM Sep 21st, 2021 09:10AM To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer for two years in a row ('19-'20), a Boston Globe Top Place to Work 6x in a row ('15-'20) and one of Fast Company's Best Workplaces for Innovators for 2021. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam), Instagram (@AlnylamPharma) and YouTube. See our community guidelines: https://bit.ly/2FcRhJy Open Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, RNAi Open 675 W Kendall St Cambridge Massachusetts US 02142 Health Care Pharmaceuticals & Biotechnology
nasdaq:alny 48171 Sep 20th, 2021 12:00AM Alnylam Pharmaceuticals 108K 1714 Open Biotechnology Sep 20th, 2021 09:12AM Sep 20th, 2021 09:12AM To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer for two years in a row ('19-'20), a Boston Globe Top Place to Work 6x in a row ('15-'20) and one of Fast Company's Best Workplaces for Innovators for 2021. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam), Instagram (@AlnylamPharma) and YouTube. See our community guidelines: https://bit.ly/2FcRhJy Open Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, RNAi Open 675 W Kendall St Cambridge Massachusetts US 02142 Health Care Pharmaceuticals & Biotechnology
nasdaq:alny 48171 Sep 19th, 2021 12:00AM Alnylam Pharmaceuticals 108K 1714 Open Biotechnology Sep 19th, 2021 03:36PM Sep 19th, 2021 03:36PM To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer for two years in a row ('19-'20), a Boston Globe Top Place to Work 6x in a row ('15-'20) and one of Fast Company's Best Workplaces for Innovators for 2021. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam), Instagram (@AlnylamPharma) and YouTube. See our community guidelines: https://bit.ly/2FcRhJy Open Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, RNAi Open 675 W Kendall St Cambridge Massachusetts US 02142 Health Care Pharmaceuticals & Biotechnology
nasdaq:alny 48171 Sep 18th, 2021 12:00AM Alnylam Pharmaceuticals 108K 1713 Open Biotechnology Sep 18th, 2021 02:26PM Sep 18th, 2021 02:26PM To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer for two years in a row ('19-'20), a Boston Globe Top Place to Work 6x in a row ('15-'20) and one of Fast Company's Best Workplaces for Innovators for 2021. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam), Instagram (@AlnylamPharma) and YouTube. See our community guidelines: https://bit.ly/2FcRhJy Open Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, RNAi Open 675 W Kendall St Cambridge Massachusetts US 02142 Health Care Pharmaceuticals & Biotechnology
nasdaq:alny 48171 Sep 17th, 2021 12:00AM Alnylam Pharmaceuticals 108K 1716 Open Biotechnology Sep 16th, 2021 10:08PM Sep 17th, 2021 07:55AM To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer for two years in a row ('19-'20), a Boston Globe Top Place to Work 6x in a row ('15-'20) and one of Fast Company's Best Workplaces for Innovators for 2021. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam), Instagram (@AlnylamPharma) and YouTube. See our community guidelines: https://bit.ly/2FcRhJy Open Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, RNAi Open 675 W Kendall St Cambridge Massachusetts US 02142 Health Care Pharmaceuticals & Biotechnology
nasdaq:alny 48171 Sep 16th, 2021 12:00AM Alnylam Pharmaceuticals 108K 1717 Open Biotechnology Sep 16th, 2021 08:07AM Sep 16th, 2021 08:07AM To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer for two years in a row ('19-'20), a Boston Globe Top Place to Work 6x in a row ('15-'20) and one of Fast Company's Best Workplaces for Innovators for 2021. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam), Instagram (@AlnylamPharma) and YouTube. See our community guidelines: https://bit.ly/2FcRhJy Open Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, RNAi Open 675 W Kendall St Cambridge Massachusetts US 02142 Health Care Pharmaceuticals & Biotechnology
nasdaq:alny 48171 Sep 15th, 2021 12:00AM Alnylam Pharmaceuticals 107K 1717 Open Biotechnology Sep 15th, 2021 10:31AM Sep 15th, 2021 10:31AM To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer for two years in a row ('19-'20), a Boston Globe Top Place to Work 6x in a row ('15-'20) and one of Fast Company's Best Workplaces for Innovators for 2021. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam), Instagram (@AlnylamPharma) and YouTube. See our community guidelines: https://bit.ly/2FcRhJy Open Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, RNAi Open 675 W Kendall St Cambridge Massachusetts US 02142 Health Care Pharmaceuticals & Biotechnology
nasdaq:alny 48171 Sep 14th, 2021 12:00AM Alnylam Pharmaceuticals 107K 1717 Open Biotechnology Sep 14th, 2021 08:42AM Sep 14th, 2021 08:42AM To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer for two years in a row ('19-'20), a Boston Globe Top Place to Work 6x in a row ('15-'20) and one of Fast Company's Best Workplaces for Innovators for 2021. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam), Instagram (@AlnylamPharma) and YouTube. See our community guidelines: https://bit.ly/2FcRhJy Open Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, RNAi Open 675 W Kendall St Cambridge Massachusetts US 02142 Health Care Pharmaceuticals & Biotechnology
nasdaq:alny 48171 Sep 13th, 2021 12:00AM Alnylam Pharmaceuticals 107K 1717 Open Biotechnology Sep 13th, 2021 07:48AM Sep 13th, 2021 07:48AM To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer for two years in a row ('19-'20), a Boston Globe Top Place to Work 6x in a row ('15-'20) and one of Fast Company's Best Workplaces for Innovators for 2021. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam), Instagram (@AlnylamPharma) and YouTube. See our community guidelines: https://bit.ly/2FcRhJy Open Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, RNAi Open 675 W Kendall St Cambridge Massachusetts US 02142 Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.